Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The new Brilacidin antifungal findings should only make Basilea more interested."
Fully agree! We have government funded research now doing discovery.
Research is still chugging along. Thank you for bringing info forward.
So does too much coffee. Patients in the ABSSSI trial that received B were cured their disease and went home.
I agree not B. The IPIX April 2022 FoxChase agreement was for "patents assignment agreement". Thanks for inputting and helping clear this up Frenchbroad. The antifungal news out of Sao Paulo University had been quite good. Hopefully we get more on that.
I know only what is in the Ipix reports. I add the underline below.
*On April 13, 2022, the Company entered a Patent Assignment Agreement with Fox Chase Chemical Diversity Center, Inc. (“FCCDC”), pursuant to which the Company assigned the title, rights and interest in and to the applications of certain patents in accordance with an earlier collaborative research agreement related to antifungal drug discovery work to which the Company had rights.
On May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC. Some of the preliminary data used in the FCCDC research program had been obtained as part of an earlier collaboration with the Company supported by funding from the National Institutes of Health. Additional payments from FCCDC to the Company may also be made in the future.
The Company and Fox Chase Chemical Diversity Center, Inc. (“FCCDC”) have a collaborative research agreement related to an antifungal drug discovery program. In exchange for a six percent fee tied to all potential future proceeds, the Company granted FCCDC all discovery, intellectual property and commercialization rights related to its share of this joint antifungal drug program which is for a compound other than Brilacidin.*
Ok, written as other than. Thank you!
It was a different compound but what was it?
I listened to the JPMorgan conference and buying more. Thanks.
Good show! "Tests showed improvements that were better than the standard medicine for Alzheimer's! Hooray!" It's a beautiful thing.
Always good to see third party validation. The stakes are getting higher I do believe. I'm hoping Bril antifungal research will make it to some government sponsored human trial.
I checked Google it's a Big beautiful complex where Shina Systems USA is located.
https://www.google.com/maps/@41.1163179,-74.1052517,3a,75y,206.26h,91.5t/data=!3m7!1e1!3m5!1sNumBEgUYCRJ7KBjclxgcIw!2e0!6shttps:%2F%2Fstreetviewpixels-pa.googleapis.com%2Fv1%2Fthumbnail%3Fpanoid%3DNumBEgUYCRJ7KBjclxgcIw%26cb_client%3Dmaps_sv.tactile.gps%26w%3D203%26h%3D100%26yaw%3D83.96801%26pitch%3D0%26thumbfov%3D100!7i13312!8i6656
I see you left off the fact that Shina Systems occupies 123-28 at this complex.
400 Rella Blvd Ste. 123-28
Montebello, NY 10901, USA
https://www.shinasystems.com/about/
Company Website reads January 9. I hope one of these days soon we see money included in a pr. Needs to happen.
January 9, 2023
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Corporate
Multiyear development and support agreement lays the foundation for the realization of an advanced software suite to enable revolutionary treatments of epilepsy and brain tumors.
WAKEFIELD, MA / January 9, 2023 – BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd. (“Shina”), a company specializing in medical imaging software platforms, in order to build on unique capabilities of Shina and accelerate the development, regulatory clearance, and commercial deployment of BeaMed’s StingRay Laser System for brain surgery.
BeaMed is the inventor and developer of the StingRay Laser System (the “StingRay System”), a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and minimally invasive surgical options for brain tumors. The activation of the StingRay System for brain surgery is done under real time MRI guidance, requiring special software for real time laser control based on MRI thermometry. In addition, special software tools will be developed to leverage the unique laser-based surgical tools developed by BeaMed. Shina brings forward decades of relevant experience in rapid development and deployment of medical imaging software suites, including advanced CT/MRI imaging platforms for strategic health companies.
“We are excited about yet another major step in the execution of BeaMed’s vision for a transformative product platform within a short time. We are confident that this partnership will help enable rapid implementation of all key requirements for FDA submission and subsequent successful product launch,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
“This agreement provides us with two key strategic advantages,” said Gil Shapira, Chief Executive Officer of BeaMed. “The first is immediate access to decades of experience and knowledge regarding design and implementation of high end medical imaging platforms including MRI access, 3D image processing and visualization, and superlative usability. The second is acceleration of our development timeline to get through FDA clearance and market launch quickly. This path underscores the execution-focused strategy of BeaMed to successfully bring its innovation to the market efficiently and expeditiously.”
BeaMed was founded by Moshe Eshkol and Gil Shapira, both highly experienced specialists in surgical lasers and medical devices. BeaMed and the development of the StingRay System are also supported by a special prestigious grant from the BIRD Foundation (https://www.birdf.com/), a bi-national organization supporting Israel-US collaboration. Gil Shapira brings forward 26+ years of engineering and product development and management experience, with over 17 years in the surgical laser industry. Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1,200 global installations and performing 50,000+ surgeries annually in over 30 countries. Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser-based medical device spin-off out of the Massachusetts Institute of Technology (MIT).
Shina Systems Ltd. develops and markets clinical image management, PACS and medical imaging analysis application software for almost 3 decades. Shina is recognized for its unique tools and intuitive, clinician-friendly application workflow. Clinically effective and technologically distinguished, Shina’s software is installed in thousands of clinical sites worldwide, including OEM partners from the top 10 global medical imaging and equipment companies.
BeaMed company website:
www.beam-med.com
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respect to specific indications; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals in the United States and other jurisdictions, including without limitation that compounds and devices may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company’s licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company’s filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company’s ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
Good to see in black and white. OM an unmet need is a nasty side effect of radiation treatment so even fair results likely gets approval. Got to get the phase3 going.
As it turns out answering questions is what Biogen et al will be doing soon.
"Congressional Inquiry into Alzheimer’s Drug Faults Its Maker and F.D.A.
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
So the price picks up and so has his FUD.
I see were starting GREEN today. Thanks doc..
Company is engaged with US and foreign biolabs proving brilacidin as a broad spectrum anti fungal and antiviral. To say the company is doing nothing is not correct. To say it will die is your opinion.
And I've found if you pay market they sell them to you at the bid. Another oddity..
Merry Christmas!
This sign came 500 years before Jesus birth, Isaiah 7:14 "Therefore the Lord himself will give you a sign: The virgin will conceive and give birth to a son, and will call him Immanuel". -God with us.
Lecanemab is showing toxicity issues and word is getting out. We shouldn't have to wait much longer for the tide to turn.
IPIX forever!!
Yes. My thoughts are multiple suitors stepping up then it's game on!
Well then you should have no concerns. Me I'm excited what the future could bring in 2023.
Good Info on deal making. Share Vault- 6-12 months from negotiation to agreement.
https://www.sharevault.com/downloads/whitepapers/ShareVault_WP_Getting_Ready_for_a_Biopharma_Partnering_Deal_FINAL.pdf?__hssc=16127337.1.1427209750908&__hstc=16127337.64b918542874cd0679102e2d18568c02.1422297947502.1425312467697.1427209750908.8&hsCtaTracking=7c7c31d5-48be-4813-9daf-bb4f6ff94240%7Caf5cb8b3-c342-4657-beb8-d6e21b94a3b3
Getting old is not a lifestyle choice. AD can hit the best of them. President Reagan was in great shape.
Correct, brilacidin has advanced through government studies. And lately has gone into anti-fungal testing.
Correction as more accurate depiction.
You don't see these headlines everyday. I expect the room to be packed.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
The PREP Act (COVID-19 Emergency Declarations) is specified to stay in place till October 1, 2024. The government would likely release funds for a nasal delivered anti-viral clinical trial just as they are paying for in-vivo now.
My bet is that the data is acceptable to the FDA because the FDA has been advising Anavex every step of the way.
Scary stuff. Sure looking forward to the nasal formula coming out party. With it I'm betting we get a shot at early onset covid.
A reason for the one tailed p test would be to check if A-273 is more effective than a marketed drug. I read a one tailed test can be used to prove effectiveness.
Well a mouses cornea anyway but I believe/guessing the mouse would have to be alive for the cornea to improve:) The language is difficult, Leo may have copy and pasted what the lab scientists reported to him. I do know the reference to murine means mouse.
You also have a Merry Christmas george h. It has been a long road. I pray for B to make longtime shareholders whole in 2023.
Company elected to avoid identifying the specific living organism used in the testing, or for that matter who conducted the tests, otherwise I'm sure you would have included those facts in your post. Am I right?
Hmm you didn't reply to my first post which cleared the air on invivo which is quite exciting. Am I bias well sure I'm a stock holder. I like the positivity coming out of the anti-fungal research.
Bias comes in many forms negative and positive.
williamssc
Re: insearchof post# 395326
Tuesday, December 13, 2022 9:39:47 AM
Post# 395328
"New in vivo data in an A. fumigatus murine fungal keratitis model showed Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control. Brilacidin-treated corneas harbored almost no viable fungus, suggesting the compound suppressed fungal proliferation within the cornea. Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight."
Study done on actual murine mouse corneas. Nice to see corneas improved after treatment with B. Huge news today.
I like B's appreciable science. If I didn't I would never post here again.
Thanks RedShoulder. God Bless and highest regards as you go through this journey with your wife.
Praying Blarcamesine gets into the hands of those who need asap.
Proving B's anti-fungal effectiveness is now in in-vivo study, so brick by brick. Looking forward to 2023.
It works wonders on A. fumigatus even improving corneal thickness per release.
"Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control. Brilacidin-treated corneas harbored almost no viable fungus, suggesting the compound suppressed fungal proliferation within the cornea."
The surface of the front layer of the eye.
Brilacidin is over whelming.